
The foveal region of primates is specialized to accumulate dietary yellow carotenoids, lutein (L) and zeaxanthin (Z) which collectively form the macular pigment (MP). These pigments selectively attenuate short-wave visible light. Although MP is often regarded mostly for its protective role in reducing photo-oxidative damage to the retina, its functional significance to everyday vision is becoming increasingly apparent. Psychophysical methods have been used for decades to measure the pigments showing direct connections to visual function. Evidence is accumulating, however, that the optical effects of MP alter perception under natural viewing conditions. For instance, increasing MP density through intervention enhances chromatic contrast, improves target visibility through simulated atmospheric blue haze, reduces glare disability and discomfort, and speeds recovery from photostress. Conversely, evidence that these optical filtering properties improve conventional visual acuity or contrast sensitivity by reducing chromatic aberration remains limited. Beyond these optical mechanisms, L and Z may also exert biochemical and cellular effects. L and Z accumulate in central nervous system tissue, where intervention studies suggest potential effects on visual processing speed, attention, memory, and neural efficiency. Emerging evidence also supports localized and systemic roles for these carotenoids in retinal development and structure and metabolic regulation. MP density varies by more than an order of magnitude among healthy individuals; while this implies corresponding individual variation in optical filtering, further research is required to determine if this variation extends proportionally to the wider structural, functional, and metabolic effects of these carotenoids.
Retinopathy of prematurity (ROP) is initiated at preterm birth. Vascular growth in the immature retina, conditioned to low intrauterine oxygen levels, is disrupted by rapid increases in oxygen which suppress oxygen-regulated growth factors. Maternally sourced essential lipids (ω-3 and ω-6 polyunsaturated fatty acids) and insulin-like growth factor-1 are also lost. Later, maturing (but avascular) retina becomes hypoxic and nutrient starved, driving a growth factor surge often causing destructive neovascularization. Current treatments address late-stage neovascular ROP by suppressing elevated vascular endothelial growth factor levels. Recent clinical studies address the initiating events, lack of specific maternally sourced lipids and growth factors, hyperoxia-induced metabolic changes, which induce suppression of normal retinal vascularization and retinal neural maturation. Early enteral supplementation with ω-3 and ω-6 polyunsaturated fatty acids reduces risk of neovascularization. Timed topical corticosteroids during early ROP which alter metabolism to promote normal vessel growth, show great promise in preventing severe disease. Risk algorithms with near 100% sensitivity and high specificity can reduce the number of screening examinations. AI-augmented photography and ultrawide field optical coherence tomography may further refine prediction, diagnosis and treatment. This review synthesizes recent clinical paradigm shifts toward early disease prevention, highlighting how novel metabolic, pharmacological, and digital health strategies can prevent ROP-related vision loss.
Slit-lamp colour photography remains a cornerstone of anterior segment documentation and longitudinal monitoring. However, conventional slit-lamp photography has seen relatively limited technological advancement compared with the rapid development of quantitative anterior-segment modalities such as AS-OCT, Scheimpflug tomography and confocal microscopy. Despite the wide diffusion of digital cameras, smartphones, and high-end slit-lamp systems, ocular surface photography (OSP) remains hampered by the absence of standardised acquisition and processing protocols. The convex, aspheric geometry of the ocular surface, off-axis illumination, peripheral defocus, automatic colour correction, and pupil-driven exposure variation in retroillumination limit reproducibility, inter-device comparability, and clinical utility. In this review we critically appraise current OSP applications across major ocular surface conditions (dry eye disease, conjunctival hyperaemia, infectious keratitis, ocular surface burns, and ocular surface neoplasia), mapping the hardware, software, and reproducibility limitations that constrain clinical practice. We then examine how these limitations propagate into artificial intelligence (AI) development, where the absence of large, well-annotated, demographically diverse OSP datasets, together with the lack of reproducible quantitative phenotypes and reliable labels, is now the principal bottleneck to clinically deployable models; we discuss patient-level data partitioning and external validation, and outline how deep learning, federated learning and foundation models can both utilise and improve OSP. Finally, we propose a minimum acquisition and dataset specification, tiered by clinical setting from research to community screening, and a staged roadmap that combines hardware standardisation (focus-stacked, illumination-controlled, colour-calibrated acquisition), interoperable metadata-rich storage (DICOM where infrastructure permits), quantitative phenotype definition, and diverse international dataset collaborations, so that the ocular surface can benefit from quantitative imaging and AI as other areas of ophthalmology have begun to.